Quest Diagnostics (DGX) has pulled impressive momentum in the Biotech sector with confirmations of strategic moves from top executives leading to major stock sales. Hitting a new 52-week high with continued growth, DGX shows potential of becoming a
'multi-bagger'. The company also declared
quarterly cash dividends with a generous hike, and impressive quarterly earnings and revenues that topped estimates. Further growth is seen with the acquisition of
Outreach Lab Services business of
University Hospitals, and select lab assets from
Allina Health. Strategic collaborations and partnerships are also in place with
Grail,
Mainz Biomed and
Sentara Health Plans. Additionally, DGX expands its presence further in Ohio and is applauded for its work in
AI and digital pathology to speed cancer diagnosis. DGX's shares are being continuously bought by large entities, indicating investor faith in the company's growth prospects. Plans are also set for hosting an
Investor day on March 19, 2025. With this, DGX stands as an innovative force in the
healthcare sector, acting as a bankable momentum stock for long-term investments.
Quest Diagnostics DGX News Analytics from Wed, 01 May 2024 07:00:00 GMT to Sat, 22 Feb 2025 06:33:53 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 6
